New data from a phase IIa trial revealed the potential of the targeted therapy across tumor types on the basis of molecular profiles

2018-03-31

Molecular information has been an important information in cancer treatment. For example, anti-Her2 therapy has been the standard treatment for Her2-positive breast cancer patients. However, genetic alternation occur in different frequencies in different cancer types. It is difficult to enroll enough patients with low incidence of targetable molecular alterations in clinical trials. Basket trial overcomes these obstacles by recruiting multiple types of cancer patients with the same genetic alternation. In a phase IIa (MyPathway) study, 230 patients with different advanced solid tumors harboring Her2, BRAF, EGFR or Hedgehog pathway alterations were treated with four targeted treatment, pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectivel. Results showed 52 (23%) patients of 14 different tumor types had objective responses. The disease control rate was 33.9% (78/230). The results demonstrated the efficacy of therapeutic strategy that treated patients across multiple tumor types by matching targeted therapy.

Source:Hainsworth JD, Meric-Bernstam F, Swanton C, et al. J Clin Oncol. 2018, 20;36(6):536-542.

青娱极品盛宴国产分类-亚洲 欧美 日韩 国产 制服-国产爆乳合集在线视频,五月色婷婷,久久热在线视频,免费网站看v片在线薰衣草